On October 18, 2025, Celcuity Inc. reported positive topline results from its VIKTORIA-1 clinical trial, showing a median progression-free survival of 9.3 months with a three-drug combination, significantly improving over 2.0 months with traditional treatment. The trial marked several milestones, with the FDA NDA submission planned for the fourth quarter of 2025.